Mathew Garnett
Mathew Garnett
Wellcome Sanger Institute
Verified email at
Cited by
Cited by
Mutations of the BRAF gene in human cancer
H Davies, GR Bignell, C Cox, P Stephens, S Edkins, S Clegg, J Teague, ...
Nature 417 (6892), 949-954, 2002
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan, MJ Garnett, SM Roe, S Lee, D Niculescu-Duvaz, VM Good, ...
Cell 116 (6), 855-867, 2004
Systematic identification of genomic markers of drug sensitivity in cancer cells
MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ...
Nature 483 (7391), 570-575, 2012
Guilty as charged: B-RAF is a human oncogene
MJ Garnett, R Marais
Cancer cell 6 (4), 313-319, 2004
Prospective derivation of a living organoid biobank of colorectal cancer patients
M van de Wetering, HE Francies, JM Francis, G Bounova, F Iorio, A Pronk, ...
Cell 161 (4), 933-945, 2015
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
W Yang, J Soares, P Greninger, EJ Edelman, H Lightfoot, S Forbes, ...
Nucleic acids research 41 (D1), D955-D961, 2012
A landscape of pharmacogenomic interactions in cancer
F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ...
Cell 166 (3), 740-754, 2016
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization
MJ Garnett, S Rana, H Paterson, D Barford, R Marais
Molecular cell 20 (6), 963-969, 2005
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling
S Huang, M H÷lzel, T Knijnenburg, A Schlicker, P Roepman, U McDermott, ...
Cell 151 (5), 937-950, 2012
ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma
SR Knezevich, MJ Garnett, TJ Pysher, JB Beckwith, PE Grundy, ...
Cancer research 58 (22), 5046-5048, 1998
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
L Broutier, G Mastrogiovanni, MMA Verstegen, HE Francies, LM Gavarrˇ, ...
Nature medicine 23 (12), 1424, 2017
Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties
MP Menden, F Iorio, M Garnett, U McDermott, CH Benes, PJ Ballester, ...
PLoS one 8 (4), e61318, 2013
A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds
A Bruna, OM Rueda, W Greenwood, AS Batra, M Callari, RN Batra, ...
Cell 167 (1), 260-274. e22, 2016
UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit
MJ Garnett, J Mansfeld, C Godwin, T Matsusaka, J Wu, P Russell, J Pines, ...
Nature cell biology 11 (11), 1363-1369, 2009
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
FM Behan, F Iorio, G Picco, E Gonšalves, CM Beaver, G Migliardi, ...
Nature 568 (7753), 511-516, 2019
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF
V Emuss, M Garnett, C Mason, R Marais
Cancer research 65 (21), 9719-9726, 2005
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
M Secrier, X Li, N De Silva, MD Eldridge, G Contino, J Bornschein, ...
Nature genetics 48 (10), 1131-1141, 2016
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer
M Michaut, SF Chin, I Majewski, TM Severson, T Bismeijer, L De Koning, ...
Scientific reports 6, 18517, 2016
The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation
C Tognon, M Garnett, E Kenward, R Kay, K Morrison, PHB Sorensen
Cancer research 61 (24), 8909-8916, 2001
Targeting the RB-E2F pathway in breast cancer
J Johnson, B Thijssen, U McDermott, M Garnett, LFA Wessels, R Bernards
Oncogene 35 (37), 4829-4835, 2016
The system can't perform the operation now. Try again later.
Articles 1–20